STW5 (Iberogast®, BAY98-7411) + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Gastrointestinal Disorders
Conditions
Functional Gastrointestinal Disorders
Trial Timeline
Jun 18, 2009 → May 3, 2013
NCT ID
NCT04059900About STW5 (Iberogast®, BAY98-7411) + Placebo
STW5 (Iberogast®, BAY98-7411) + Placebo is a phase 2 stage product being developed by Bayer for Functional Gastrointestinal Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT04059900. Target conditions include Functional Gastrointestinal Disorders.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04059900 | Phase 2 | Completed |
Competing Products
20 competing products in Functional Gastrointestinal Disorders